Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04545697
Other study ID # 20554
Secondary ID NCI-2020-07023
Status Completed
Phase N/A
First received
Last updated
Start date September 18, 2020
Est. completion date February 28, 2021

Study information

Verified date May 2021
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients surviving with advanced prostate cancer frequently encounter time points in their disease course that require choosing among multiple options regarding systemic therapy. Interventions to improve shared decision-making through patient support measures such as question listing, and audio recording and summarizing of consultations have been shown to improve patient-reported measures of decision making quality, e.g. decreased decisional conflict and regret. However, the feasibility of consultation recording and summarizing with mobile health (mHealth) technology on patient-owned smartphones is unknown. The investigators will conduct a single-arm trial to determine feasibility and acceptability of a clinician-prompted, patient administered smartphone audio recording application and a service to summarize the recordings (Patient Support Corps or PSC), in improving decision-making quality among patients with chemotherapy-naive, progressive, metastatic castration-resistant prostate cancer (mCRPC). This trial will inform the design and conduct of a larger trial evaluating broader scale implementation of this intervention.


Description:

The intervention (provision of instructions on how to install/use the app and how to share the recording with the PSC) will take place 7-60 days before the upcoming oncology consultation. PSC will provide a summary within a week of the consultation. Primary Objective: To determine the percentage of enrolled participants who use a clinician-prompted, patient-administered smartphone application to create an audio recording of an outpatient oncology visit. Secondary Objectives: 1. To determine the percentage of enrolled participants who listen to the audio recording within 1 week after the visit. 2. To determine the percentage of enrolled participants who request and receive a written summary of the consultation from the Patient Support Corps within 1 week after the visit. 3. To determine whether audio recording and summarization change decision-making quality measures. 4. To determine whether audio recording and summarization change provider-reported workload and other outcomes. 5. To determine whether audio recording and summarization change the frequency of follow-up communication between participant and clinic staff. Participants will be followed via electronic medical record review for 2 weeks after consultation


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date February 28, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Prostate cancer of any histology. 2. Metastatic castrate-resistant Prostate Cancer (mCRPC) 3. Progression per any Prostate Cancer Working Group 3(PCWG3) criterion. 4. Has never received chemotherapy 5. Currently receiving or has previously received any androgen-signaling inhibitors (ASI) (abiraterone, enzalutamide, apalutamide, or darolutamide) that was discontinued due to progression 6. 18 years of age or older. 7. Able to read, speak, and write in English. 8. Has an upcoming genitourinary (GU) medical oncology appointment (in-person or Zoom video visit) at University of California, San Francisco (UCSF) within 7-60 days of enrollment. 9. Has access to and ability to use an iPhone (iOS) or Android smartphone. 10. Patient's UCSF oncology provider agrees to be recorded. Exclusion Criteria: 1. Lack of decision-making capacity to provide consent to this trial. 2. Uncorrectable hearing or visual impairment hindering the ability to perform necessary tasks in the trial. 3. Any neurocognitive or psychiatric disorder hindering the ability to perform necessary tasks in the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Medcorder
Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of enrolled participants who utilized the application Proportion of enrolled participants who create a complete audio consultation recording of the appointment using the application, measured by application metrics, at 1 week post-consultation along with 95% confidence interval will be reported. Up to 2 weeks after the appointment
Secondary Proportion of enrolled participants who listened to audio recording within 1 week after the visit Proportion of enrolled participants who listen to the recording, measured by participant-reported survey at 1 week post-consultation along with 95% confidence interval will be reported. Up to 2 weeks after the appointment
Secondary Proportion of enrolled participants who obtain written summary of the consultation Proportion of enrolled participants who request and receive a written summary of the consultation from the Patient Support Corps (PSC) within 1 week after the visit along with 95% confidence interval will be reported. Up to 2 weeks after the appointment
Secondary Mean participant-reported CollaboRATE scores The CollaboRATE is a 3-item questionnaire developed to measure shared decision making in reference to the most recent appointment the participant may have had with the oncologist.
The questions are as follows: (i) How much effort was made to help you understand your health issues? (ii) How much effort was made to listen to what matters most to you about your health is-sues? (iii) How much effort was made to include what matters most to you in choosing what to do next? Each response ranges from a score of 0-9, with a response of 0 = "No effort was made" and 9="Every effort was made". Higher total scores represent more shared decision making.
Up to 2 weeks after the appointment
Secondary Mean score of participant reported Decision Regret Scale (DRS) The DRS is a 5-item questionnaire where participants are asked to reflect on a past decision, and then asked to indicated the extent to which they agree or disagree with the statement in the regret scale by indication a number from 1 (Strongly) to 5 (Strongly Disagree) that best indicated their level of agreement. Scores are converted to a 0-100 scale with a lower scores indicating less regret. Up to 2 weeks after the appointment
Secondary Mean change in scores on the Informed subscale of the Decisional Conflict Scale (DCS) from baseline The "Informed" subscale of the DCS consists of 3 items which measure the degree that the participant feel informed, with scores that range from 0 (strongly agree) to 4 (Strongly disagree). Scores are summed and then converted to a scale of 0-100, with lower indicating a greater degree of feeling informed. For analyzing changes in DCS information subscale, a two-tailed paired sample t-test will be used to determine whether the mean difference between pre- and post-consultation survey scores is 0 or not. Baseline and up to 2 weeks after the appointment
Secondary Mean perceived change in work burden provider-reported workload and other outcomes The change in work burden will be determined using a provider-reported workload survey to determine whether audio recording produced a change in work burden at 1 week post-consultation among providers with enrolled participants. There are 5 possible responses: "Decreased work", "No Change", "A little more work", "Some more work", and "A lot more work". Up to 2 weeks after the appointment
Secondary Mean perceived change in provider-patient relationship quality The change in provider-patient relationship quality will be determined using a provider-reported survey to determine whether audio recording produced a change in the provider patient relationship at 1 week post-consultation among providers with enrolled participants. There are 5 possible responses: "Negatively", "Somewhat Negatively", "No change", "Somewhat Positively", and "Positively". Up to 2 weeks after the appointment
Secondary Mean change in number of participant-initiated telephone call or portal message encounters over time Changes in the frequency of follow-up communication between participant and clinic staff in the electronic health record from baseline (2 weeks pre-consultation to consultation) to post-consultation (consultation to 2 weeks post-consultation). Baseline and up to 2 weeks after the appointment
See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Recruiting NCT04533958 - Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy N/A
Not yet recruiting NCT06009549 - A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
Withdrawn NCT05771896 - Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC Phase 3
Completed NCT01981122 - A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer Phase 2
Completed NCT01233557 - Biomarkers of Bone Resorption in Metastatic Prostate Cancer N/A
Completed NCT01012141 - Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer Phase 2
Recruiting NCT04067713 - Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
Active, not recruiting NCT04332744 - Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Completed NCT02278055 - Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT04193657 - Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
Completed NCT02260817 - Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer Phase 3
Terminated NCT00216060 - Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy Phase 3
Recruiting NCT04070209 - Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Phase 2
Recruiting NCT04925648 - Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction Phase 2
Completed NCT01303705 - Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Phase 1
Completed NCT01560923 - Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Phase 2